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Chronic thromboxane inhibition preserves function of rejecting
rat renal allografts
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Chronic thromboxane inhibition preserves function of rejecting rat
renal allografts. Increased production of thromboxane (TX) by rejecting
renal allografts results in significant and partially reversible renal
vasoconstriction. In this study, we evaluated the potential benefit of
chronically administering the TX synthetase inhibitor OKY-046 from
the time of transplantation in a rat model of acute renal allograft
rejection. In animals which received 75 mg/kg/day of OKY-046 by
intermittent i.p. injection, allograft function was not improved, but
renal throniboxane production was not significantly inhibited. How-
ever, animals which received an equivalent dose of OKY-046 by
continuous intra-arterial infusion for four days maintained clearances of
inulin (4.46 0.79 mI/mm/kg) and PAH (23.86 1.81 mI/mm/kg) at
normal levels not different from non-rejecting isografts (4.83 0.93 and
18.33 2.55 mI/mm/kg, respectively). In contrast, animals which
received continuous infusion of saline vehicle alone developed a
significant reduction in renal function (C1,: 1.58 0.27 mI/mm/kg;
CPAH: 9.12 1.51 mI/minlkg) by the fourth day after transplantation.
Intra-arterial infusion of OKY-046 significantly reduced four-day allo-
graft TXB2 production, as well as urinary TXB2 excretion, but had no
effect on allograft production of PGE2 or 6-ketoPGF1,,. Despite the
beneficial effects on allograft function, OKY-046 neither altered the
morphologic appearance of the cellular infiltrate nor the systemic
proliferative and cytotoxic anti-donor cellular immune responses. Six
days following transplantation, renal TXB2 production was only par-
tially inhibited in animals given continuous infusions of OKY-046, and
remained markedly elevated. This partial inhibition of TX production
resulted in a slight but insignificant functional improvement. These
studies demonstrate that TX is a hemodynamic mediator of primary
importance during the early stages of acute renal allograft rejection, but
its role in later stages is unclear. Furthermore, these findings suggest
that thromboxane antagonists may be a novel and potentially useful
form of adjunctive therapy for acute renal allograft rejection.
Acute renal allograft rejection is characterized by inflamma-
tory cell infiltration and reductions in glomerular filtration rate
and renal blood flow. Intense renal cortical vasoconstriction
occurs during rejection [1—3] often resulting in ischemic damage
within the graft [4]. Furthermore, impairment of excretory
function is often more marked than would be expected from the
morphologic appearance of the allograft. However, until re-
cently, little has been known about the actual effector mecha-
nisms which reduce renal function and blood flow during
rejection.
Observations from several laboratories have demonstrated
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that vasoconstrictor eicosanoids are produced during rejection
[5—9]. For example, urinary excretion of immunoreactive throm-
boxane B2 (iTXB2) is elevated in renal transplant recipients
during episodes of acute rejection [5, 6]. Renal thromboxane
production increases during rejection and may account for the
increase in urinary iTXB2 observed clinically and in experimen-
tal models [7—11]. In addition, acute administration of a specific
thromboxane synthetase inhibitor improves glomerular filtra-
tion rate and renal blood flow in rejecting rat renal allografts [8].
However, the effect of more prolonged administration of throm-
boxane antagonists on the course of renal allograft rejection has
not been previously described. Furthermore, in other models of
renal immune injury, beneficial effects of chronically adminis-
tered thromboxane antagonists have been difficult to demon-
strate [12].
In this study, we administered the specific thromboxane
synthetase inhibitor OKY-046 (sodium-3-[4-( 1-imidazolylmeth-
yl)phenyl]propenoate) to rats with kidney allografts to examine
the effects of chronic thromboxane synthetase inhibition on
renal hemodynamic function and eicosanoid production. We
compared the effectiveness of the thromboxane antagonist
when given by intermittent intraperitoneal injection versus
continuous intra-arterial infusion. In addition, since the effects
of thromboxane antagonists on immune responsiveness in vivo
have not been well defined, we compared allograft histology
and various assays of systemic anti-donor alloimmunity in
animals which received OKY-046 compared to controls which
received vehicle alone. When adequate thromboxane synthe-
tase inhibition was achieved, we demonstrated for the first time,
complete preservation of renal function for four days in this
aggressive model of acute renal allograft rejection without any
other immunosuppressive therapy. In addition, we confirm the
importance of effective renal thromboxane inhibition and the
difficulty in achieving adequate inhibition by usual routes of
administration. These studies suggest that thromboxane antag-
onists may be a novel and potentially useful form of adjunctive
therapy for the treatment of acute renal allograft rejection.
Methods
Animals
Inbred male rats of the PVG (RT1C) and AC! (RTl) strains
were initially obtained from OLAC Ltd. (Bicester, UK). These
animals were subsequently maintained and bred in our isolated
colony under local and N.I.H. guidelines. All rats were 8 to 12
weeks old when these studies were performed.
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Rat renal transplants were performed as previously described
[8] using a modification of the technique of Fabre, Lim and
Morris [131. In the allograft studies, kidneys from ACI (RT1)
rats were transplanted into fully allogeneic PVG (RTIC) recipi-
ents. For comparison, a control group of isografted animals in
which rejection does not occur was also evaluated (N = 5). In
this group, kidneys from ACI donors were transplanted into
their littermates. The transplantation procedure was identical
for isografts and allografts. The donor kidney, ureter and
bladder were harvested en bloc, including the renal artery with
a 3 mm aortic cuff and the renal vein with a 3 mm vena caval
cuff. Anastamoses were created between these vascular cuffs
and the recipient abdominal aorta and vena cava, respectively.
Total ischemic time averaged 35 to 40 minutes. Donor and
recipient bladders were attached dome to dome. The right
native kidney was removed at the time of transplant and the left
native kidney was removed through a flank incision 24 to 48
hours later. Overall surgical mortality was less than 20% and
was not different between OKY and vehicle treated groups.
OKY-046 administration
In a pilot study, allografted animals were given OKY-046 (N
= 5) or saline vehicle (N = 5) at a dose of 75 mg/kg/day by
intraperitoneal (i.p.) injection three times per day. This dose of
inhibitor far exceeds the dose of a similar agent (OKY-l58l)
previously reported to inhibit urinary thromboxane excretion in
rats following 5/6 renal ablation [14]. Because renal thrombox-
ane production was not significantly inhibited using this treat-
ment regimen, we devised a method for continuous intra-arte-
rial infusion of OKY-046 or its saline vehicle as shown in Figure
Similar to the method of Ruers et al[i5], we used a minios-
motic pump (Alzet Corp., Palo Alto, California, USA) with a
tapered PE-60 catheter attached to the pump's flow moderator.
After priming for 24 hours in saline, the pump was placed
subcutaneously during the transplantation procedure. The cath-
eter was passed through the abdominal wall and tied into the
aortic cuff of the allograft in order to accomplish direct delivery
of OKY-046 or saline vehicle into the renal artery. In this way,
OKY-046 at a dose of 50 sg/kgImin (N = 26) or saline vehicle (N
= 25) were administered by continuous intra-arterial infusion
from the time of transplantation. The dose administered in this
fashion (73 mg/kg/day) was equivalent to the dose used in the
initial i.p. studies. In addition, this dose represents the near
maximal dose of OKY-046 which can be administered by this
technique because of the relatively poor solubility of OKY-046
in aqueous solution and the limited fluid reservoir of the
mini-osmotic pumps (< 2 ml).
Urinary eicosanoid measurements
Three days following transplantation, animals with mini-os-
motic pumps were placed into metabolic cages and 24 hour
urines were collected on ice for measurement of urinary eico-
sanoid excretion.
Renal clearance studies
Clearances of inulin and PAH were measured on days 4 and
6 following transplantation. On the day of study, animals were
Fig. 1. Method for continuous intra-arterial infusion of OKY-046 or
saline vehicle. A tapered PE-60 catheter is attached to the flow
moderator of a mini-osmotic pump (designated OP in the diagram). The
catheter is passed through the abdominal wall and ligated into the aortic
cuff of the allograft allowing direct delivery of OKY-046 or vehicle into
the transplant renal artery.
anesthetized with nembutal (40 mg/kg) and a polyurethane
catheter (PE-240) was inserted into the trachea to facilitate
spontaneous respiration. The right carotid artery was cannula-
ted to permit periodic sampling of arterial blood and to measure
arterial blood pressure (Gould-Statham strain gauge). The jug-
ular vein was cannulated and a volume of normal saline equal to
1.5% of body weight was infused to replace surgical losses.
Following this volume replacement, priming doses of carboxyl-
'4C-inulin and glycyl-3H-PAH (New England Nuclear, Boston,
Massachusetts, USA) in saline were given followed by a
continuous infusion at a rate of 0.05 ml/l00 g!min. The allograft
ureter was cannulated with a PE-lO catheter.
After a 45-minute equilibration period, urine was collected
for two consecutive, 30-minute clearance periods. Arterial
blood samples were obtained at the midpoint of each urine
collection. Tritium and '4C radioactivity were measured in
plasma and urine with a dual channel Isocap 300 liquid scintil-
lation system (Nuclear Chicago). C1, and CpAH were then
calculated using standard formulas.
Renal perfusion
Immediately following completion of the in vivo clearance
studies, allografts were perfused with a single pass, cell-free
perfusion system in order to assess renal eicosanoid production
independently of systemic contamination. Using a modification
vc
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of previously described methods [8], a polished metal perfusion
catheter was inserted into the left femoral artery and advanced
to the level of the transplant anastomosis. After the catheter
was secured, perfusion was begun and the aorta was ligated
above the level of the transplant anastamosis. The renal vein
was then cannulated with a flared PE-160 catheter. Kidneys
were perfused with Krebs-Henseleit solution containing 2 mM
calcium. Perfusate was warmed (37°C), oxygenated (95% 02,
5% C02) and delivered at a rate of 8 mllmin. After a 20-minute
"washout" period, two samples of renal venous effluent were
collected over 30 minutes to determine renal eicosanoid pro-
duction. All samples were collected on ice and 5 ml aliquots
were stored at —70°C. Samples were later thawed, extracted
and then assayed for TXB2, PGE2and 6-keto PGF1 by radio-
immunoassay. TXB2 and 6-ketoPGF1 are the stable, physio-
logically inactive metabolites of TXA2 and PGI2, respectively.
Radioimmunoassays
Eicosanoids were extracted from renal venous effluent using
AASP C18 cartridges (Analytichem International, Harbor City,
California, USA). Unmetabolized TXB2 and PGE2 in urine
were separated by HPLC using a Waters Model 840 system and
a Pecosphere HS3-Cl8 column [16]. Eicosanoids were eluted
with a linear solvent gradient from 100% 0.017 orthophosphoric
acid to 100% acetonitrile over 10 minutes at 3 mI/mm. Appro-
priate fractions were collected based on retention times of
known TXB2 and PGE2 standards, and eluate was dried under
nitrogen and resuspended in buffer.
TXB2, POE2 and 6-keto PGF1 were quantitated by radioim-
munoassay [17]. All values were corrected for recovery of
tritiated standards added to original samples. Antisera and
standards were purchased from ICN Immunobiologicals (Lisle,
Illinois, USA) for the TXB2 and POE2 assays, and AM!-
Seragen Inc. (Boston, Massachusetts, USA) for the 6-keto
PGF1 assay. Samples and standards were incubated with a
mixture of antisera and a known amount of tritiated standard at
4°C for 20 hours. After incubation, free eicosanoid was ad-
sorbed with dextran coated charcoal, and tritium remaining in
the supernatant was measured with a liquid scintillation counter
(T.M. Analytical, Elk Grove Village, Illinois, USA). The un-
knowns were compared with a standard curve in which the
logarithm of the concentration was plotted against the logit of
the BIB0 value.
Allograft morphology
Sections of allografted kidney that had been fixed in formalin
were stained with hematoxylin and eosin and Periodic Acid
Schiff stains. Renal histology was evaluated by two pathologists
(PR and FPS) masked to the experimental groups.
Assays of cellular immunity
Recipient spleens were aseptically removed from allograft
recipients on the fourth day following transplantation and were
prepared in complete culture media as described previously
[18]. These unseparated splenocyte suspensions were used to
assay specific anti-donor immune responsiveness as described
below.
Mixed lymphocyte responses (MLR). Five x i04 unseparated
recipient splenocytes were incubated with 2 X l0 irradiated
(5000 rads) AC! stimulators at 37°C in 5% CO2. After four days
of incubation, the cells were pulsed with 1 Ci of 3H-thymidine
and harvested 18 hours later on filter strips. Cell bound radio-
activity was quantitated using a beta-counter (1219 Rackbeta,
LKB, Turku, Fl). Values are expressed as the mean counts per
minute (cpm) of triplicate cultures standard deviation of the
mean.
Cell mediated lympholysis (CML). Splenocytes from allograft
recipients were prepared as above and CML assays were
performed as described previously [18]. Briefly, 3 x 106 sple-
nocytes isolated from recipient animals were incubated with
irradiated AC! stimulators for three days at 37°C in 5% CO2.
Following this culture period, the effector cells were collected,
washed and added to 96 well "V" bottom plates at concentra-
tions necessary to achieve the desired effector-target ratios with
1 x io concanavalin A (Con A) stimulated, 51Cr-labelled ACI
lymphoblast targets. Following a four hour incubation, plates
were centrifuged for five minutes and a 125 d aliquot of
supernatant was removed from each well for counting. Maxi-
mum lysis was obtained by adding 100 l of 1 N HC1 to 100 pi
of 51Cr-labelled targets, and spontaneous release was deter-
mined by incubation of 100 l of labeled target cells with 100 d
of complete medium alone.
The percentage of specific 51Cr release was calculated for
each effector: target cell ratio by the formula:
cpm (experimental) — cpm (spontaneous release) x 100%
cpm (max. release) — cpm (spontaneous release).
Cytotoxic T-lymphocyte precursor assay (pCTL). Cytotoxic
T-lymphocyte precursor frequency was determined by a limit-
ing dilution assay as described previously [181 with minor
modifications. Unfractionated spleen cell preparations from
allograft recipients were added in limiting dilutions to 96-well
V-well plates (Limbro Flow Labs, McClean, Virginia, USA) in
replicates of 24. Dilutions of responder splenocytes ranged from
5 x l0 to 7.8 x 102 cells per well. Irradiated AC! splenocyte
stimulators (2 x l0 cells/well) and irradiated autologous naive
PVG splenocyte feeder cells (1 x l0 cells/well) were added in
complete medium containing supernatant from Lewis strain
splenocytes stimulated with Concanavalin A (Con A) as a
source of IL-2. The final concentration per well was 20% Con A
supernatant. Following seven days in culture, all wells were
gently resuspended and 150 jl from each well was transferred
to new 96-V well plates. 2 x l0 51Cr-labelled Con A-trans-
formed ACT splenocytes were then added to each well in 50 l
volumes and incubated for four hours (37°C, 5% CO2). The
plates were then centrifuged at 500g for five minutes and cell
free supernatants were harvested from each well. 51Cr activity
in these supernatants was quantitated in a gamma counter (1272
Clinigamma, LKB). Cytotoxic precursor frequency was then
calculated using the minimum chi-square method of analysis
[191.
Proliferative T-lymphocyte precursor assay (pPTL). Limited
numbers of splenocytes from allograft recipients were added to
96-well round-bottom plates (Linbro, Flow Labs) in complete
medium in replicates of 24. Irradiated AC! stimulators (1 x l0
cells/well) and irradiated naive PVG splenocyte feeder cells (1
x 10" cells/well) were added in complete medium without IL-2
supplementation. Following four days in culture (37°C, 5%
C02), each well was pulsed with 1 Ci of 3H-thymidine and
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harvested 18 hours later on filter strips. Cell-bound radioactiv-
ity was quantitated using a beta counter. Positive wells were
considered to be those with cpm exceeding the sum of the mean
plus three times the standard deviation of cpm from 24 wells
which contained stimulator cells without responders. Precursor
frequency was calculated using the minimum chi-square meth-
od of analysis [19].
Statistics
Data are presented as the mean standard error of the mean,
except for the MLC experiments which are expressed as the
mean standard deviation. In the clearance and in situ
perfusion studies, individual values for each animal represent
the mean of values measured during at least two clearance
periods or sample collections. For comparisons between two
groups, statistical significance was assessed using an unpaired
t-test. For comparisons between three groups, statistical anal-
ysis was performed by one-way analysis of variance followed
by Bonferroni's procedure for multiple pairwise comparisons
[201.
Results
OKY-046 at 75 mg/kg/day administered by intraperitoneal
injection every eight hours had no significant effect on hemo-
dynamic function or thromboxane production by six-day renal
allografts. Clearances of inulin (0.21 0.10 mI/mm/kg in the
OKY group vs. 0.19 0.11 ml/min/kg in the vehicle group) and
PAH (2.32 1.45 ml/min/kg in the OKY group vs. 2.30 1.89
mI/mm/kg in the vehicle group) were negligible in both the OKY
and vehicle treated groups. However, there was no difference
between renal thromboxane production by the i.p. OKY-treat-
ed group (5433 2443 pg/mm) and the group which received
only vehicle (5662 3696 pglmin).
Because of the failure of OKY-046 to inhibit renal thrombox-
ane production when administered by intraperitoneal injection,
the thromboxane synthetase inhibitor was infused continuously
in to the allograft artery as described in Methods. The effect of
continuous intra-arterial infusion of OKY-046 on renal allograft
function is shown in Figure 2. Inulin clearance (C1,,) by the
control group given saline vehicle (N = 13) was significantly
reduced (1.58 0.27 mI/mm/kg) when compared to isografts
four days following transplantation (4.83 0.93 mI/mm/kg; P <
0.005). In contrast, C1,, by four day allografts treated with
continuous infusions of OKY-046 (N = 10) was significantly
greater than that of the group given vehicle alone (4.46 0.79
mi/mm/kg; P < 0,0005), and was not different from that of four
day isografts. As shown in Figure 2B, chronic intra-arterial
administration of OKY-046 had a similar effect on PAH clear-
ance (CPAH). Four days following transplantation, CPAH by the
group which received continuous infusion of OKY-046 (23.86
1.81 ml/min/kg) was significantly greater than that of the group
given vehicle alone (9.12 1.51 ml/min/kg; P < 0.0005) and was
not different from CPAH of non-rejecting isografts (18.33 2.55
ml/min/kg).
Figure 4 shows the effect of continuous infusion of OKY-046
on renal eicosanoid production in these animals four days
following transplantation. TXB2 production measured in renal
venous effluent of in situ perfused allografts was significantly
reduced from 136 12 pg/mm in the vehicle treated group to 69
20 pg/mm (P < 0.025) in the group which received OKY-046.
Fig. 2. The effect of continuous intra-arterial infusion of OKY-046 on
C1,, and CPAH of allografts 4 days following transplantation. P <
0.005 vs. vehicle control.
Intra-arterial administration of OKY-046 had no significant
effect on allograft production of PGE2 (131 40 pg/mm in the
vehicle group vs. 171 15 pg/mm in the OKY-046 group) or the
PGI2 metabolite 6-keto PGF1,, (111 25 pg/mm in the vehicle
group vs. 165 59 pg/mm in the OKY-046 group). Excretion of
unmetabolized, "native" TXB2 was also reduced from 38 7
pg/hr in the vehicle treated group to 13 4 pg/hr with OKY-046
treatment (P < 0.01). However, OKY-046 had no significant
effect on urinary POE2 excretion (214 37 pg/hr in the vehicle
group vs. 200 65 pg/hr in the group wlcich received OKY-
046).
Histomorphologic examination of formalin fixed sections of
four day allografts from both the vehicle and OKY treated
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Table 1. Renal allograft function and thromboxane production
GFR
mi/mm/kg
6 day
CPAH
ml/,nin/kg
6 day
Renal TXB2 production
pg/mm
6 day 4 day
OKY-046 0.77 0.31 4.24 1.89 983 203 69 20
Vehicle 0.19 0.06
0.05 <P < 0.1
1.03 0.43
0.05 <P < 0.1
4440 884 136 12
P < 0.005 P < 0.025
Fig. 3. The effect of continuous intra-arterial infusion of OKY-046 on
eicosanoid production by renal allografts 4 days following transplan-
tation. Symbols are: () vehicle, (U) OKY-046. * P < 0.025 vs. vehicle
control.
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Fig. 4. A representative cell-mediated lympholysis (CML) experiment
at various effector-to-target (EIT) ratios. CML responses, expressed as
% specific 5tCr release from ACI targets, were significantly elevated in
splenocytes from vehicle (0) and OKY-046 (•) treated allograft recip-
ients compared to naive, non-transplanted PVG controls (x). There
was no significant difference in donor-specific CML responses between
the vehicle and OKY-046 treated groups.
groups showed cellular infiltrates typical of ongoing rejection.
Despite the marked difference in renal function, there were no
significant differences in the severity or pattern of the observed
infiltrates between the groups. All allografts showed polymor-
phonuclear leukocyte infiltrates around peritubular capillaries
and mononuclear cell infiltrates throughout the cortex and
perivascular spaces. No necrosis or thrombi were observed in
either group.
Several assays of cellular alloimmunity were performed to
determine whether intra-arterial administration of OKY-046
produced alterations in anti-donor immune responsiveness
which might play a role in the observed improvement of
function in four day allografts. Mixed lymphocyte responses
(MLR) and cell-mediated lympholysis (CML) of splenocytes
from animals which received continuous infusions of vehicle (N
= 5) or OKY-046 (N = 5) were compared to those of naive PVG
controls (N = 5). The proliferative responses (expressed as
3H-thymidine uptake in counts per minute) of splenocytes from
vehicle (34657 8878 cpm) and OKY treated animals (40362
13876 cpm) to stimulator ACI lymphoblasts were not signifi-
cantly different from one another and were increased compared
to naive PVG controls (8010 6017 cpm; P < 0.005 vs. both
groups). Syngeneic (PVG) stimulator cells produced no signif-
icant increase in 3H-thymidine uptake in any of the groups.
Figure 4 depicts CML responses of splenocytes from vehicle
(N = 5) and OKY treated (N = 5) allograft recipients four days
following transplantation compared to naive PVG controls (N =
5). There was no significant difference in donor-specific CML
response between the vehicle and OKY treated groups. CML
responses in both allografted groups were elevated significantly
compared to the naive PVG controls. No significant lysis of
PVG targets was evident with effector cells from any group.
Specific anti-donor cytotoxic and proliferative T-lymphocyte
precursor frequencies were measured by limiting dilution as-
says of unfractionated spleen cell populations from allografted
animals four days following transplantation. The range of pCTL
were essentially equivalent for animals which received vehicle
(1/462 to 1/4585) or OKY-046 (1/514 to 1/1300), and were
markedly elevated compared to non-transplanted controls. Sim-
ilarly, pPTL were not different between the vehicle (1/664 to 1/
2472) and OKY-046 (1/1597 to 1/2928) groups.
To evaluate the effect of continuous intra-arterial infusion of
OKY-046 on the later stages of rejection, we also evaluated
renal function and eicosanoid production in allografts six days
following transplantation. As demonstrated in Table 1, C1 by
the group which received intra-arterial infusion of OKY-046
(0.77 0.31 ml/min/kg; N = 10) tended to be higher than
controls (0.19 0.06 ml/min/kg; N = 7), although this differ-
ence was not statistically significant (0.05 <P <0.1). Similarly,
CPAH in the OKY-046 group (4,24 1.89 ml/min/kg) tended to
be higher, but was not significantly different from CPAH of
vehicle treated controls (1.03 0.43 mllmin/kg; 0.05 < P <
0.1). In contrast to the group which received OKY-046 by i.p.
injection, renal TXB2 production was significantly reduced in
six day allografts given continuous infusions of OKY-046 (983
203 pg/mm) compared to controls (4440 884 pg/mm; P <
0.005). However, renal TXB2 production remained markedly
elevated in both groups of six day allografts, compared to four
day allografts. There were no significant differences in six day
allograft production of PGE2 and 6-keto PGF1a) between the
vehicle and OKY-046 treated groups.
Discussion
During acute rejection there is a marked increase in produc-
tion of the vasoconstrictor eicosanoid thromboxane A2 within
the rejecting allograft [7—9]. We have shown that this increase in
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TXA2 production results in significant reversible vasoconstric-
tion, since acute inhibition of thromboxane production im-
proves hemodynamics in rejecting rat renal allografts [8]. How-
ever, acute thromboxane antagonism results in only modest
hemodynamic improvement and does not restore allograft func-
tion to normal. The effect of chronic thromboxane synthetase
inhibition on the course of renal allograft rejection has not been
previously examined. Furthermore, in other models of immune-
mediated renal disease, beneficial effects of chronic thrombox-
ane antagonists have been difficult to demonstrate [12].
In rats with orthotopic cardiac allografts, Foegh and associ-
ates have demonstrated that chronic administration of throm-
boxane antagonists in combination with low doses of azathio-
prine [21] and cyclosporine [221 prolonged graft survival when
compared to low doses of either immunosuppressive agent used
alone. In their studies, allograft survival was not improved
when thromboxane antagonists were given alone. Unfortu-
nately, since only relative changes in urinary TXB2 excretion
were measured, the effectiveness of allograft TX inhibition
attained in these studies is not clear.
In the present study, we evaluated the effects of chronic
administration of the specific thromboxane synthetase inhibitor
OKY-046 in a model of aggressive renal allograft rejection.
When 75 mg/kg/day of OKY-046 was given by intraperitoneal
injection, allograft function was not improved but renal throm-
boxane production was not significantly inhibited. However,
when an equivalent dose of OKY-046 was given by continuous
intra-arterial infusion, animals maintained GFR and CPAH at
normal levels for four days following transplantation. In addi-
tion, continuous intra-arterial administration of OKY-046 sig-
nificantly reduced TXB2 production by four day allografts
without affecting renal production of PGE2 or 6-keto PGF1.
Urinary excretion of TXB2 and 2,3-dinor TXB2 were also
reduced with intra-arterial OKY-046 administration. Despite
this substantial improvement in renal hemodynamic function,
continuous infusion of OKY-046 did not significantly affect
allograft histology or systemic cellular immunity, as assessed
by in vitro MLR, CML, pPTL and pCTL assays. In six day
allografts, renal TXB2 production was partially inhibited by
chronic intra-arterial infusion of OKY-046, but remained mark-
edly elevated. This partial inhibition of thromboxane produc-
tion in six day allografts did not result in a significant improve-
ment in renal function.
We have previously shown that acute administration of a
thromboxane synthetase inhibitor increased RBF by 58% in
rejecting rat renal allografts [8]. Despite this significant im-
provement, allograft function remained well below normal. In
contrast, continuous administration of thromboxane antagonist
to allografted animals in the present study resulted in normal-
ization of GFR and CPAH to levels no different than non-
rejecting renal isografts. The more marked effect of chronic
thromboxane antagonism in this model may result from preven-
tion of ischemic damage which occurs during unmodified rejec-
tion [4] through inhibition of thromboxane production from the
time of transplant. This observation further underscores the
primary importance of TXA2 as a hemodynamic mediator
during the early stages of acute rejection.
While PGE2 and PG!2 suppress a number of macrophage and
lymphocyte-mediated processes [23—27], there is little evidence
to suggest that TXA2 has any important role in immunoregula-
tion. Thromboxane synthetase inhibitors have been reported to
inhibit lymphocyte proliferation and cytotoxicity in vitro [28,
29]. However, Ceuppens et al demonstrated that this effect was
most likely related to endoperoxide shunting and increased
production of PGE2 or PG!2 rather than a direct effect of
thromboxane inhibition [30]. Furthermore, these authors found
that physiologic concentrations of the TXA2 analog U466l9 had
no significant effect on lymphocyte proliferation.
Although we found that OKY-046 treatment restored four
day allograft function to normal levels, there were no differ-
ences in allograft histology between the OKY-046 and vehicle
treated groups. In contrast to other anti-rejection agents,
chronic thromboxane synthetase inhibition produced no detect-
able diminution of systemic anti-donor proliferative or cyto-
toxic cellular immune responses. For comparison, cyclosporine
treated rats with well-functioning renal allografts develop sig-
nificant depression of systemic cell-mediated lymphocytotox-
icity within the first week following transplantation [31]. Thus,
our data suggest that the beneficial effects of OKY-046 in this
model are related to the hemodynamic consequences of TXA2
antagonism rather than a major inhibition of cellular immunity.
However, a subtle effect of OKY-046 on systemic immune
response or a local effect on immune function of cells within the
graft cannot be excluded.
In current clinical practice, corticosteroids are commonly
used for treatment of acute renal allograft rejection. Among
their many pharmacologic effects, corticosteroids have been
demonstrated to inhibit phospholipase activity and eicosanoid
formation in vitro [32]. Therefore, some of the beneficial effects
of steroids in the treatment of rejection may be related to
inhibition of thromboxane synthesis. Since complications of
immunosuppressive therapy continue to be a major source of
morbidity following transplantation, the use specific thrombox-
ane inhibitors might allow for reductions in immunosuppressive
drug doses without compromising graft function.
The role of thromboxane in producing renal dysfunction in
the later stages of rejection cannot be determined from this
study. Although intra-arterial OKY-046 administration did not
significantly improve function of six day allografts, inhibition of
renal TXB2 production was incomplete. However, the problem
was not simply a technical failure of the infusion system since
total TXB2 production was significantly reduced to 25% of
control values. By six days following transplantation, inflam-
matory cell infiltration and anatomical disruption of the allograft
become more marked [8, 33]. In this setting, higher drug
concentrations may be required to achieve effective thrombox-
ane inhibition. Furthermore, endoperoxides may accumulate
when thromboxane synthetase is inhibited [34]. These com-
pounds bind to thromboxane receptors and can cause vasocon-
striction and platelet aggregation [35]. Therefore, in the later
stages of rejection when renal thromboxane production is
markedly stimulated, generation of vasoconstrictor endoper-
oxides may mask the beneficial effects of thromboxane synthe-
tase inhibition. Combined administration of a thromboxane
synthetase inhibitor and receptor antagonist might be more
effective in this situation.
In summary, chronic thromboxane inhibition reversed the
functional abnormalities associated with acute renal allograft
rejection in rats four days after transplantation. Thus, throm-
boxane A2 is an important hemodynamic mediator during the
30 Coffman et a!: Thromboxane inhibition during rejection
early stages of acute renal allograft rejection. Despite its
dramatic effect on allograft function, chronic thromboxane
synthetase inhibition is not associated with significant suppres-
sion of systemic cellular immunity. The role of thromboxane in
producing renal dysfunction in the later stages of rejection is
unclear, but other factors are obviously important. Effective
thromboxane inhibition may be a useful adjunct in the treatment
of renal allograft rejection.
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